Key Word(s): 1. Bagdi; 2. Bangladesh; 3. Clinical trials; 4. Ethnic people; Presenting Author: VADAMALAINATHAN GOVINDASAMY Additional Authors: MOHANPRASAD VIRUKALPATTIGOPALRATNAM, VENKATA KRISHNAN Corresponding Author:

VADAMALAINATHAN GOVINDASAMY Affiliations: VGM HOSPITAL-INSTITUTE OF GASTROENTEROLOGY; PSG INSTITUTE OF MEDICAL SCIENCES Objective: Acute HBV infection is successfully cleared in more than 95% of immunocompetent individuals, while the rest may develop either chronic HBV ATR inhibitor infection or rarely Fulminant Hepatitis. The role of Antivirals in acute HBV infection has not been evaluated in controlled trials. The aim of the present study is to assess the safety and efficacy of two different Antiviral therapies in management of Acute Viral hepatitis B compared to Placebo. Methods: Thirty

consecutive patients with Biochemical and serological evidence of Acute Hepatitis B were randomized to three treatment groups. Pts in Group A received Placebo, those in Group B received once a day Lamivudine 100 mg with Adefovir 10 mg PO, pts in Group C received Telbivudine 600 mg along with Tenofovir 300 mg PO per day, till ALT and AST normalized.. Results: Baseline Characteristics were comparable in all Palbociclib research buy three groups. At 4 weeks, ALT and AST normalization was achieved in 0%, 40% and 40% of patients in Groups A,B& C respectively (p < 0.001) which increased to 30%,100% and 100% at 8 weeks (p < 0.001). Although HBsAg was lost in all these patients, the time taken for HbsAg loss was significantly lesser in patients of Groups B & C (84 Vs 98 days, p<0.001) than in patients of Gr A ( 164 days ,p < 0.001). medchemexpress Seroconversion with spontaneous development of Anti Hbs occurred in 60%,

80%,80%, of pts with mean Anti Hbs titers being 134 IU/ml, 957 IU/Ml, 832 IU/ml respectively Conclusion: Although Acute hepatitis B is cleared spontaneously in more than 95% of Immunocompetent individuals, treatment with Antivirals appears definitely beneficial in shortening the duration of illness, more rapid normalization of biochemical markers and more marked immunological clearance when compared to Placebo. Key Word(s): 1. acute hepatitis B; 2. antiviral therapy; 3. telbivudine; 4. lamivudine; Presenting Author: POH YEN LOH Additional Authors: KM FOCK, JESSICA TAN, EK TEO, TL ANG Corresponding Author: POH YEN LOH Affiliations: Changi General Hospital Objective: Response to hepatitis C treatment with peg-interferon and ribavirin is affected by many factors. Asians have been shown to have better response in previous studies. Current study is to look at the response of hepatitis C treatment in different genotypes and the effect of peg-interferon dose adjustments to its outcomes. Methods: All treatment naïve hepatitis C patients treated with peg-interferon alpha 2a and ribavirin between 2007 and 2011 were retrospectively analysed in a centre in Singapore.